Zhejiang Int'l Group Co Ltd

Zhejiang Int'l Group Co Ltd maintains a market price of 11.79 CNY, with a market capitalization of 6.66 billion CNY. The company's price-to-earnings ratio is 13.29, and its price-to-book ratio is 1.3, indicating a moderate valuation relative to its book value. The enterprise value to EBITDA ratio is 12.65, and the enterprise value to revenue ratio is 0.32, suggesting a relatively low valuation in terms of revenue. The company's profitability metrics show a return on equity of 9.82% and a return on assets of 2.99%. These figures are below the typical thresholds for strong profitability in the pharmaceutical industry, indicating that the company is generating returns, but not at a level that would be considered exceptional. The gross profit of 2.36 billion CNY and operating income of 856.56 million CNY further support this assessment. Zhejiang Int'l Group Co Ltd's revenue is concentrated in the pharmaceuticals segment, with no significant geographic diversification disclosed. The company's total revenue of 33.68 billion CNY is primarily derived from its core pharmaceutical operations. There is no indication of substantial revenue from other business lines or international markets. The company's growth trajectory is modest, with no significant revenue growth disclosed in the latest financial data. The capital expenditure of -237.15 million CNY indicates a reduction in investment in physical assets, which may suggest a focus on cost management or a shift in strategic priorities. The outlook for the current fiscal year does not indicate a substantial increase in revenue or profitability. The company faces a medium liquidity risk, as indicated by the risk assessment. The debt-to-equity ratio of 0.82 suggests a moderate level of leverage, and the current ratio of 1.36 indicates that the company has sufficient current assets to cover its current liabilities. However, the key flag of negative net cash after subtracting total debt highlights a potential liquidity constraint. The dilution risk is assessed as low, with no immediate pressure for share issuance. Recent events and filings do not indicate any significant changes in the company's operations or financial strategy. The company's financial statements and disclosures do not highlight any major legal, regulatory, or operational risks that would significantly impact its performance. The absence of recent significant events suggests a stable operating environment for the company.